The US health regulator USFDA has provided its final approval to the Glenmark Pharmaceutivals for triamcinolone acetonide ointment that is used in the treatment of various skin conditions.

It has said in a BSE filing that “Glenmark Pharmaceuticals Inc, USA has been granted final approval by the US Food and Drug Administration (USFDA) for triamcinolone acetonide ointment USP, 0.5 percent.”

Approval has been provided for generic version of triamcinolone acetonide ointment USP, 0.5 percent of Perrigo New York, Inc. This ointment is used for treating various skin conditions that includes eczema, dermatitis, allergies and rash.

Read EquityPandit’s Nifty Pharma Outlook for this week